Bone: Giant cell tumour of bone

2003-06-01   Ramses G Forsyth , Pancras CW Hogendoorn 

1.N. Goormaghtigh Institute of Pathology, 5 Blok A, University Hospital Ghent, B-9000 Ghent, Belgium
2.Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. J.V.M.G.Bovee@lumc.nl

Summary

Atlas Image
A characteristic well-defined eccentric, lytic subchondral lesion involving the epiphysis and metaphysis. The borders are well defined and usually not sclerotic. Pathologic fracture is present in 5-10% of giant cell tumours. Dynamic MRI shows a fast uptake and a slow wash out of contrast.

Abstract

Review on giant cell tumor of bone, with data on clinics, histopathology and genetics

Classification

Note

Giant cell tumor of bone is a locally aggressive primary bone neoplasm.

Clinics and Pathology

Phenotype stem cell origin

Primitive mesenchymal stromal cell.

Embryonic origin

Mesoderm.

Etiology

The exact origin is still unknown, but data obtained from ultrastructural analyses and cell cultures, as well as novel molecular data, suggest that the stromal cell, or mononuclear spindle cell, is neoplastic. The mononuclear rounded cells and the osteoclastic giant cells are seen as reactive. Therefore, some suggest that stromal cell tumour is a better name, because this fits more precisely the concept of the mononuclear spindled cell (stromal cell) as neoplastic.

Epidemiology

This tumour represents 8% of all primary and approximately 20% of benign primary bone tumours. Mostly affecting adults in the third, fourth and fifth decade of life (72%). It is very rarely seen under the age of 10 years (1,3%). There is a slight female predominance (male/female ratio: 46,6%/53,4%).

Clinics

Pain of several weeks to months duration and a constantly expanding mass on X-ray, primary in the epiphysis, leading to cortex destruction, pathological fracture and soft tissue invasion. Finally ulceration of the skin occurs if not threatened. A pathological fracture could occasionally be the first sign of this tumour.
Atlas Image
Mixture of three cellular components composites the tumour: tumoral spindle shaped mononuclear cells, reactive rounded mononuclear cells and diffusely scattered osteoclast type giant cells. Note that mitoses are strictly limited to the first cell type.

Pathology

A mixture of four components can be distinguished:
  • S pindled-shaped and rounded mononuclear cells,
  • Osteoclastic-type giant cells and small blood vessels.
    The spindle-shaped mononuclear cells are regarded as neoplastic. This cell type is thought to arise from the primitive mesenchymal stromal cell. Conventional mitotic figures are restricted to mononuclear cells. If atypical forms or strong nuclear atypia is noted, a secondary sarcomatous malignancy is almost always present. Secondary changes may be present like osteoid deposits, foci of fibrosis, collections of foamy cells or cystic degeneration. Secondary aneurysmal bone cyst formation is present in 6,5% of the cases. Mostly this is restricted to younger patients (median of 14 years).

    In the 2013 WHO classification, grading of histopathological features of GCTB is not considered predictive for clinical behaviour including risk for recurrent or metastatic disease. Originally, giant cell tumors of bone were histological graded into 3 grades according to Jaffe (1940) or into 4 grades (Netherlands Committee on Bone Tumours).

  • Treatment

    Surgical intervention is the treatment of choice and therapeutic inhibition of osteoclast formation and activity with denosumab (RANK-RANKL inhibitor) provides another modality of treatment. Mostly a curettage followed by local adjuvant cryosurgery or phenol instillation is sufficient to eradicate this lesion and to save the joint. The use of polymethylmetacrylate for filling the cavity after curettage additively decreases the percentage of recurrences. An added advantage of using cement is that recurrences are detected sooner. Sometimes en bloc resection is needed to be curative. Pulmonal metastases are treated by local excision.

    Evolution

    Non-treatment always leads to destruction of cortical bone, to soft tissue invasion and finally to ulceration of the skin. Local recurrences can occur following proper treatment, mostly indicating less radical initial resection.

    Prognosis

    Good, despite of recurrences and pulmonary metastases. In general much is depending on the surgical technique and expertise in combination with the histological grade of this tumour. Although pulmonary metastases may occur in rare cases, angiovascular invasion does not have any significant influence on its prognosis. The mortality rate due to giant cell tumour is about 4%.

    Cytogenetics

    Cytogenetics morphological

    The most frequent chromosomal anomaly is telomeric association. Comparing telomere length of giant cell tumours to this of leukocytes of the same patient, a reduction has been demonstrated. Most commonly affected telomeres are 11p, 13p, 14p, 15p, 19q, 20q and 21p.

    Note

    When confronted with a rearrangement, especially concerning 16q22 or 17p3, an associated aneurysmal bone cyst should be excluded.

    Genetics

    Note

    A specific driver mutation in the histone 3.3 gene H3F3A (p.Gly34) was recently identified in approximately 92% of giant cell tumours of bone. H3F3A mutation detection can be used as a diagnostic tool for the distinction of giant cell tumor of bone from other giant cell-containing tumors. A subset of the mutations can be easily detected using a G34W mutation specific antibody.

    Bibliography

    Pubmed IDLast YearTitleAuthors
    285050002017H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone.Amary F et al
    241627392013Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.Behjati S et al
    17289461992Giant cell tumor of bone. Chromosomal analysis of 48 specimens and review of the literature.Bridge JA et al
    264573572015Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.Cleven AH et al
    97781111998Giant cell tumor of bone: a clinicopathologic study of prognostic factors.Masui F et al
    86407281996Chromosomal anomalies exclusive of telomeric associations in giant cell tumor of bone.McComb EN et al
    74974391995Cytogenetics of fine needle aspiration biopsies of sarcomas.Molenaar WM et al
    287975022017Giant Cell-Containing Tumors of Bone.Orosz Z et al
    274998982015Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics.Presneau N et al
    119183222002Clonality studies in giant cell tumor of bone.Schwartz HS et al
    111060782000Cytogenetic-morphologic correlations in aneurysmal bone cyst, giant cell tumor of bone and combined lesions. A report from the CHAMP study group.Sciot R et al
    94609511998Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up.Siebenrock KA et al
    83302781993Cytogenetic study of 249 consecutive patients examined for a bone tumor.Tarkkanen M et al
    106430091999Telomeric fusion is a major cytogenetic aberration of giant cell tumors of bone.Zheng MH et al

    Citation

    Ramses G Forsyth ; Pancras CW Hogendoorn

    Bone: Giant cell tumour of bone

    Atlas Genet Cytogenet Oncol Haematol. 2003-06-01

    Online version: http://atlasgeneticsoncology.org/solid-tumor/5150/bone-giant-cell-tumour-of-bone

    Historical Card

    0000-00-00 Bone: Giant cell tumour of bone by  Arjen Cleven,Judith Bovée 

    Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. J.V.M.G.Bovee@lumc.nl